2 results
Approved WMOCompleted
Primary: to assess the effect of intravenous (IV) ozanezumab (15 mg/kg once every 2 weeks) compared to placebo on the physical function and survival of ALS patients over a treatment period of 48-weeks.Secondary (major): other clinical outcomes,…
Approved WMOWill not start
The purpose of the research trial is to assess if heart failure markers and clinical end-points are influenced by 24 hours of AV-node stimulation (AVNS) in acutely decompensated heart failure (ADHF) patients.Primary Objective(s)The primary objective…